AR and prostate carcinoma: Enzalutamide (4) and apalutamide (5) were eventually identified as two lead candidates for preclinical development on the grounds of in vitro evaluation of their capability of agonistic and antagonistic activity of AR signaling in a castration-resistant LNCaP/AR prostate cancer cell model [20].